Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Immunogenicity of ASKB1202 vs Bevacizumab in Healthy Chinese Subjects
NCT03115762Phase 1Unknown
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Jul 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of ASKB1202 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), glioblastoma (GBM) and 3 more (3 arms), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration up to 100 days, Area Under the Curve from time 0 to last measurable concentration up to 100 days and 1 more. Status: unknown.
02
Drugs
ASKB1202
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)glioblastoma (GBM)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03115762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115762.